| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 6: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 2 | 25 | 309 1991 JOURNAL OF EXPERIMENTAL MEDICINE 173(3):699-703 SAMPAIO EP; SARNO EN; GALILLY R; COHN ZA; KAPLAN G THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES | 291 | 504 |
| 1502 | 1 | 4 | 292 1990 PRESSE MEDICALE 19(15):722-722 SAMSON J; KUFFER R; RADEFF B THALIDOMIDE TREATMENT OF CHOICE OF APHTHAE IN HIV-INFECTION | 2 | 2 |
| 1503 | 51 | 221 | 964 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 1504 | 12 | 17 | 1892 2004 DERMATOLOGY 208(2):149-152 Sander CS; Kaatz M; Elsner P Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide | 0 | 0 |
| 1505 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
| 1506 | 10 | 28 | 1884 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(8):1021-1022 Sano H; Noguchi T; Tanatani A; Miyachi H; Hashimoto Y N-phenylphthalimide-type cyclooxygenase (COX) inhibitors derived from thalidomide: Substituent effects on subtype selectivity | 0 | 0 |
| 1507 | 13 | 23 | 1937 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
| 1508 | 4 | 7 | 1680 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 2 | 2 |
| 1509 | 0 | 0 | 1378 2002 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
| 1510 | 6 | 14 | 534 1996 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 111(1):13-17 SantosMendoza T; FavilaCastillo L; Oltra A; Tamariz J; Labarrios F; EstradaParra S; EstradaGarcia I Thalidomide and its metabolites have no effect on human lymphocyte proliferation | 7 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 0 | 0 | 627 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
| 1512 | 7 | 23 | 438 1995 BIOLOGICAL & PHARMACEUTICAL BULLETIN 18(9):1228-1233 SASAKI K; SHIBATA Y; HASHIMOTO Y; IWASAKI S BENZYLPHTHALIMIDES AND PHENETHYLPHTHALIMIDES WITH THALIDOMIDE-LIKE ACTIVITY ON THE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA | 7 | 18 |
| 1513 | 3 | 14 | 843 1999 MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
| 1514 | 5 | 7 | 682 1998 BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
| 1515 | 0 | 0 | 506 1996 ARTHRITIS AND RHEUMATISM 39(9):1353-1353 Sato EI; Assis LSS; Furtado R Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE) | 0 | 0 |
| 1516 | 0 | 0 | 1363 2002 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
| 1517 | 6 | 24 | 879 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 1518 | 3 | 5 | 235 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
| 1519 | 11 | 23 | 1844 2004 ANNALS OF PHARMACOTHERAPY 38(5):808-811 Sayarlioglu M; Kotan MC; Topcu N; Bayram I; Arslanturk H; Gul A Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease | 0 | 0 |
| 1520 | 0 | 4 | 39 1982 ARCHIVES OF DERMATOLOGY 118(8):536-536 SAYLAN T; SALTIK I THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 42 | 59 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 0 | 0 | 1452 2002 FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
| 1522 | 0 | 9 | 277 1990 GEBURTSHILFE UND FRAUENHEILKUNDE 50(11):899-900 SCHAEFER C; SPIELMANN H COCAINE AND PREGNANCY - SHADES OF THE THALIDOMIDE TRAGEDY | 0 | 0 |
| 1523 | 0 | 38 | 208 1987 EUROPEAN JOURNAL OF PEDIATRICS 146(1):63-67 SCHAFER KH; KRAMER M INFANTILE HYPERTROPHIC PYLORIC-STENOSIS AFTER PRENATAL EXPOSURE TO THALIDOMIDE | 0 | 0 |
| 1524 | 9 | 39 | 1760 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
| 1525 | 0 | 0 | 1594 2003 ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
| 1526 | 8 | 27 | 794 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 1527 | 5 | 25 | 1548 2002 RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
| 1528 | 0 | 0 | 1448 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
| 1529 | 12 | 27 | 1794 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 2 | 3 |
| 1530 | 17 | 32 | 1924 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3269-3276 Schey SA; Fields P; Bartlett JB; Clarke IA; Ashan G; Knight RD; Streetly M; Dalgleish AG Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 0 | 0 | 778 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 1532 | 0 | 0 | 387 1994 BLOOD 84(10):A431-A431 SCHLEGEL PG; FERNANDEZ LP; BAKER J; CHEN Y; CHAO NJ THALIDOMIDE DOES NOT MODULATE THE IL-2 RESPONSE OF ACTIVATED JURKAT CELLS AS MEASURED BY BETA-GAL-ACTIVITY AND BY IL-2 PRODUCTION | 1 | 1 |
| 1533 | 4 | 4 | 1144 2001 BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
| 1534 | 8 | 22 | 504 1996 ARCHIVES OF TOXICOLOGY 70(11):749-756 Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse | 3 | 7 |
| 1535 | 3 | 15 | 265 1989 TOXICOLOGY LETTERS 45(1):23-33 SCHMAHL HJ; HEGER W; NAU H THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .2. CHEMICAL-STABILITY, STEREOSELECTIVITY OF METABOLISM AND RENAL EXCRETION IN THE MARMOSET MONKEY | 7 | 17 |
| 1536 | 0 | 11 | 224 1988 ARCHIVES OF TOXICOLOGY 62(2-3):200-204 SCHMAHL HJ; NAU H; NEUBERT D THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .1. CHIRAL INVERSION AND PLASMA PHARMACOKINETICS IN THE MARMOSET MONKEY | 8 | 18 |
| 1537 | 0 | 0 | 196 1986 TERATOLOGY 33(2):A57-A57 SCHMAHL HJ; WINKLER K; HEGER W; BARRACH HJ; NAU H PHARMACOKINETICS OF THE TERATOGENIC AND NONTERATOGENIC THALIDOMIDE ANALOGS EM-12 AND SUPIDIMID IN THE RAT AND MARMOSET MONKEY | 0 | 0 |
| 1538 | 9 | 20 | 545 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 9 | 18 |
| 1539 | 0 | 3 | 1 1980 ACTA GENETICAE MEDICAE ET GEMELLOLOGIAE 29(4):295-297 SCHMIDT M; SALZANO FM DISSIMILAR EFFECTS OF THALIDOMIDE IN DIZYGOTIC TWINS | 1 | 8 |
| 1540 | 1 | 17 | 66 1983 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 16(2):105-109 SCHMIDT M; SALZANO FM CLINICAL-STUDIES ON TEENAGE BRAZILIAN VICTIMS OF THALIDOMIDE | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 1 | 1 | 1069 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(1):87-87 Schmutz JL; Barbaud A; Trechot P Buccal lichen after thalidomide | 0 | 0 |
| 1542 | 5 | 6 | 1572 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
| 1543 | 1 | 1 | 1574 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1187-1187 Schmutz JL; Barbaud A; Trechot P Thalidomide: the first case with gynecomastia | 0 | 0 |
| 1544 | 0 | 0 | 204 1987 ARCHIVES OF GYNECOLOGY AND OBSTETRICS 242(1-4):944-945 SCHNEIDER HPG; MUHLENSTEDT D; OCHS H PUBERTY, SEXUALITY AND PARTNERSHIP IN YOUNG-PEOPLE WITH THALIDOMIDE-INDUCED DEFORMITIES | 0 | 0 |
| 1545 | 8 | 21 | 606 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
| 1546 | 0 | 0 | 104 1984 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 111(3):285-286 SCHNITZLER L THALIDOMIDE IN HAILEY-HAILEY DISEASE - GOOD BUT PALLIATIVE RESULTS | 4 | 11 |
| 1547 | 1 | 1 | 1001 2000 JOURNAL OF CHILD NEUROLOGY 15(12):838-838 Schoeman JF Thalidomide therapy in childhood tuberculous meningitis | 3 | 4 |
| 1548 | 3 | 10 | 1166 2001 CHILDS NERVOUS SYSTEM 17(6):370-372 Schoeman JF; Ravenscroft A; Hartzenberg HB Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess | 5 | 5 |
| 1549 | 4 | 17 | 1000 2000 JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 11 |
| 1550 | 13 | 26 | 1919 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 7 | 46 | 1186 2001 ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
| 1552 | 0 | 0 | 60 1983 ACTA NEUROLOGICA SCANDINAVICA 68(3):184-184 SCHRODER JM; MATTHIESEN T EXPERIMENTAL THALIDOMIDE NEUROPATHY - THE MORPHOLOGICAL CORRELATE OF REDUCED CONDUCTION-VELOCITY | 0 | 0 |
| 1553 | 1 | 17 | 136 1985 ACTA NEUROPATHOLOGICA 65(3-4):285-292 SCHRODER JM; MATTHIESEN T EXPERIMENTAL THALIDOMIDE NEUROPATHY - THE MORPHOLOGICAL CORRELATE OF REDUCED CONDUCTION-VELOCITY | 5 | 7 |
| 1554 | 7 | 18 | 429 1995 ACTA NEUROPATHOLOGICA 89(5):415-419 SCHRODER JM; SELLHAUS B; WOHRMANN T; KOGEL B; ZWINGENBERGER K INHIBITORY EFFECTS OF THALIDOMIDE ON CELLULAR PROLIFERATION, ENDONEURIAL EDEMA AND MYELIN PHAGOCYTOSIS DURING EARLY WALLERIAN DEGENERATION | 6 | 9 |
| 1555 | 0 | 0 | 1810 2003 PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
| 1556 | 0 | 0 | 452 1995 DRUG SAFETY 12(6):364-369 SCHULER U; EHNINGER G THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS | 25 | 36 |
| 1557 | 1 | 14 | 124 1984 MUSCLE & NERVE 7(5):362-368 SCHWAB BW; AREZZO JC; PALDINO AM; FLOHE L; MATTHIESSEN T; SPENCER PS RABBIT SURAL NERVE RESPONSES TO CHRONIC TREATMENT WITH THALIDOMIDE AND SUPIDIMIDE | 4 | 6 |
| 1558 | 0 | 0 | 1304 2002 ARTHRITIS AND RHEUMATISM 46(9):S480-S481 Schwartz KH; Agle LMA; Lehman TJA Thalidomide therapy of systemic onset JIA: Continued success. | 0 | 2 |
| 1559 | 2 | 7 | 1590 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
| 1560 | 0 | 39 | 44 1982 DERMATOLOGICA 165(4):355-362 SCOLARI F; HARMS M; GILARDI S THALIDOMIDE IN THE TREATMENT OF CHRONIC LUPUS-ERYTHEMATOSUS | 7 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 0 | 0 | 437 1995 ARTHRITIS AND RHEUMATISM 38(9):769-769 SCOVILLE CD OPEN TRIAL OF THALIDOMIDE IN THE TREATMENT OF RHEUMATOID-ARTHRITIS | 0 | 0 |
| 1562 | 0 | 0 | 665 1998 ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
| 1563 | 3 | 3 | 1169 2001 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 19(3):360-361 Scoville CD Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis | 5 | 5 |
| 1564 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| 1565 | 0 | 0 | 1902 2004 FASEB JOURNAL 18(4):A68-A68 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide (Thd) decreases Fibronectin (FN)-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines | 0 | 0 |
| 1566 | 0 | 0 | 1929 2004 JOURNAL OF INVESTIGATIVE MEDICINE 52(2):S403-S403 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide decreases fibronectin-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines. | 0 | 0 |
| 1567 | 0 | 16 | 1285 2002 AMERICAN BIOLOGY TEACHER 64(7):495-500 Seidman LA; Warren NN Frances Kelsey & thalidomide in the US: A case study relating to pharmaceutical regulations | 0 | 0 |
| 1568 | 6 | 27 | 1277 2001 SYNTHESIS-STUTTGART (7):999-1000 Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B Microwave promoted synthesis of a rehabilitated drug: Thalidomide | 0 | 2 |
| 1569 | 10 | 18 | 1493 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
| 1570 | 0 | 0 | 1110 2001 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 16 | 25 | 1702 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 5 | 9 |
| 1572 | 36 | 60 | 1164 2001 CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
| 1573 | 8 | 16 | 1422 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44 Seyahi E; Ozdogan H; Masatlioglu S; Yazici H Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient | 0 | 4 |
| 1574 | 12 | 20 | 988 2000 IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
| 1575 | 19 | 36 | 802 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
| 1576 | 5 | 34 | 406 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 1577 | 0 | 36 | 29 1981 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 13(6):553-562 SHANNON EJ; MIRANDA RO; MORALES MJ; HASTINGS RC INHIBITION OF DENOVO IGM ANTIBODY-SYNTHESIS BY THALIDOMIDE AS A RELEVANT MECHANISM OF ACTION IN LEPROSY | 32 | 41 |
| 1578 | 8 | 22 | 603 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
| 1579 | 8 | 25 | 463 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 1580 | 3 | 22 | 532 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 0 | 0 | 526 1996 FASEB JOURNAL 10(6):303-303 Shannon EJ; Sandoval F; Krahenbuhl J Hydrolysis of thalidomide abrogates its ability to enhance IL-2 or to suppress TNF-alpha. | 0 | 0 |
| 1582 | 8 | 21 | 604 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 18 | 19 |
| 1583 | 11 | 22 | 1468 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
| 1584 | 3 | 13 | 166 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
| 1585 | 0 | 0 | 153 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(1):165-166 SHANNON EJ; TRUMAN RW; CHRISTY SA; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO A T-INDEPENDENT ANTIGEN - DNP FICOLL | 0 | 0 |
| 1586 | 3 | 4 | 618 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
| 1587 | 11 | 39 | 602 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
| 1588 | 1 | 5 | 430 1995 AIDS 9(6):658-659 SHARPSTONE D; ROWBOTTOM A; NELSON M; GAZZARD B THE TREATMENT OF MICROSPORIDIAL DIARRHEA WITH THALIDOMIDE | 14 | 34 |
| 1589 | 0 | 0 | 936 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| 1590 | 2 | 8 | 177 1986 ARTHRITIS AND RHEUMATISM 29(10):1296-1296 SHEEHAN NJ THALIDOMIDE NEUROTOXICITY AND RHEUMATOID-ARTHRITIS | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 10 | 22 | 859 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
| 1592 | 17 | 48 | 1310 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 11 |
| 1593 | 0 | 0 | 56 1982 TERATOLOGY 25(2):A75-A75 SHEPARD TH; SHIOTA K BIOACTIVATION OF THALIDOMIDE BY A MONKEY LIVER FRACTION IN A RAT LIMB CULTURE SYSTEM | 0 | 0 |
| 1594 | 4 | 28 | 186 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
| 1595 | 0 | 0 | 17 1981 INTERNATIONAL JOURNAL OF DERMATOLOGY 20(3):220-220 SHESKIN J THALIDOMIDE - REPLY | 0 | 0 |
| 1596 | 0 | 7 | 12 1981 DERMATOLOGICA 163(2):145-150 SHESKIN J; GORODETSKY R; WEINREB A; LOEWINGER E IRON CONTENT OF SKIN BEFORE AND AFTER THALIDOMIDE TREATMENT OF LEPRA REACTION - A PRELIMINARY-REPORT | 0 | 5 |
| 1597 | 0 | 5 | 11 1981 DERMATOLOGICA 162(2):86-90 SHESKIN J; GORODETZKY R; LOEWINGER E; WEINREB A INVIVO MEASUREMENTS OF IRON, COPPER AND ZINC IN THE SKIN OF PRURIGO NODULARIS PATIENTS TREATED WITH THALIDOMIDE | 3 | 11 |
| 1598 | 0 | 14 | 86 1983 HAUTARZT 34(4):168-170 SHESKIN J; MUCKTER H; FRANKUS E SUPIDIMIDE, A NON-TERATOGENIC ANALOG OF THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS | 2 | 2 |
| 1599 | 0 | 0 | 1343 2002 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
| 1600 | 0 | 0 | 1062 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 0 | 0 | 767 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 1602 | 8 | 26 | 762 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 11 | 17 |
| 1603 | 6 | 23 | 1883 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 1604 | 6 | 23 | 836 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 1605 | 0 | 16 | 298 1990 TOXICOLOGY LETTERS 50(2-3):309-318 SHIOTA K; UWABE C; YAMAMOTO M; ARISHIMA K SUSCEPTIBILITY TO CYCLOPHOSPHAMIDE AND THALIDOMIDE OF FETAL-RAT LIMB BUDS GRAFTED IN ATHYMIC (NUDE) MICE | 0 | 0 |
| 1606 | 9 | 23 | 1230 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 12 | 22 |
| 1607 | 1 | 144 | 120 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
| 1608 | 1 | 6 | 1564 2003 AMERICAN JOURNAL OF GASTROENTEROLOGY 98(1):221-222 Shurafa M; Kamboj G Thalidomide for the treatment of bleeding angiodysplasias | 1 | 2 |
| 1609 | 1 | 9 | 1408 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
| 1610 | 0 | 0 | 1364 2002 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 6 | 32 | 832 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 1612 | 2 | 23 | 419 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
| 1613 | 15 | 44 | 1954 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
| 1614 | 6 | 12 | 574 1997 ANALYTICA CHIMICA ACTA 339(1-2):91-97 Simmons BR; Lush RM; Figg WD A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum | 8 | 10 |
| 1615 | 0 | 0 | 1906 2004 GASTROENTEROLOGY 126(4):A629-A629 Simon M; Gornet JM; Plane C; Allez M; Colombel JF; Sabate JM; Cortot A; Modigliani R; Lemann M Long term efficacy and toxicity of thalidomide in Crohn's disease | 0 | 0 |
| 1616 | 1 | 1 | 1030 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
| 1617 | 50 | 73 | 1086 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
| 1618 | 53 | 61 | 1307 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 17 | 21 |
| 1619 | 9 | 37 | 852 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
| 1620 | 0 | 0 | 678 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 3 | 15 | 1836 2004 AMERICAN JOURNAL OF HEMATOLOGY 76(1):66-68 Sinisalo M; Hietaharju A; Sauranen J; Wirta O Thalidomide in POEMS syndrome: Case report | 0 | 0 |
| 1622 | 5 | 5 | 459 1995 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 19(1):128-129 SIRE S; FRAISSE P; REY D; JACQUEMIN C; KEMPF G; PARTISANI M; LANG JM EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF ESOPHAGEAL ULCERS IN AIDS | 2 | 2 |
| 1623 | 0 | 0 | 1113 2001 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
| 1624 | 0 | 0 | 542 1996 JOURNAL OF INVESTIGATIVE DERMATOLOGY 106(4):845-845 Smith C; Friednash M; Nguyen C; Knauf T; Walsh P Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model | 2 | 3 |
| 1625 | 5 | 51 | 561 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 6 |
| 1626 | 1 | 2 | 184 1986 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 64(3):P66-P66 SMITH NJ; JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL NERVE-CONDUCTION STUDIES IN PATIENTS TAKING THALIDOMIDE | 0 | 0 |
| 1627 | 2 | 3 | 685 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
| 1628 | 9 | 10 | 695 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 5 | 5 |
| 1629 | 1 | 5 | 722 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
| 1630 | 2 | 2 | 395 1994 BRITISH MEDICAL JOURNAL 309(6952):477-477 SMITHELLS RW THALIDOMIDE MAY BE A MUTAGEN | 8 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 3 | 18 | 326 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
| 1632 | 8 | 11 | 1560 2003 ADAMANTIADES-BEHCET'S DISEASE 528:585-589 Sohn S; Lee ES; Lee SI; Kim YA; Kwon HJ; Bang D; Lei S Therapeutic effect of thalidomide through cytokine and chemokine regulation in herpes simplex virus-induced Behcet's disease-like animal model | 0 | 0 |
| 1633 | 5 | 13 | 519 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
| 1634 | 3 | 5 | 502 1996 ARCHIVES OF DISEASE IN CHILDHOOD 74(1):64-65 Soler RA; Migliorati C; vanWaes H; Nadal D Thalidomide treatment of mucosal ulcerations in HIV infection | 11 | 14 |
| 1635 | 0 | 0 | 1661 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
| 1636 | 0 | 0 | 1136 2001 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 1637 | 10 | 55 | 737 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
| 1638 | 2 | 32 | 1503 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
| 1639 | 0 | 0 | 1627 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
| 1640 | 0 | 0 | 1858 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 0 | 0 | 820 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 1642 | 3 | 44 | 797 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 1643 | 0 | 0 | 994 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| 1644 | 9 | 23 | 1531 2002 MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
| 1645 | 0 | 0 | 772 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 1646 | 0 | 0 | 921 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 1647 | 1 | 10 | 1570 2003 AMERICAN JOURNAL OF MEDICINE 115(4):332-334 Staak JO; Glossmann JP; Esser JM; Diehl V; Mietz H; Josting A Thalidomide for systemic capillary leak syndrome | 0 | 0 |
| 1648 | 0 | 0 | 641 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
| 1649 | 5 | 5 | 725 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
| 1650 | 2 | 8 | 1558 2003 ACTA DERMATO-VENEREOLOGICA 83(4):302-303 Staumont-Salle D; Magro L; Piette F; Thomas P; Jouet JP; Catteau B Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 0 | 0 | 946 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 1652 | 16 | 37 | 1147 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 19 | 31 |
| 1653 | 0 | 0 | 1192 2001 GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
| 1654 | 19 | 36 | 1792 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
| 1655 | 18 | 36 | 1317 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 11 | 25 |
| 1656 | 1 | 2 | 1165 2001 CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| 1657 | 7 | 61 | 247 1988 TERATOLOGY 38(3):229-239 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 40 | 64 |
| 1658 | 3 | 12 | 295 1990 TERATOLOGY 41(2):241-242 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 1659 | 3 | 10 | 297 1990 TERATOLOGY 41(2):245-246 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 1 | 3 |
| 1660 | 26 | 174 | 893 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 9 | 41 | 1057 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
| 1662 | 0 | 0 | 31 1981 TERATOLOGY 23(2):A63-A64 STEPHENS TD; MCNULTY TR IS THALIDOMIDE EMBRYOPATHY A RESULT OF NEUROPATHY - NO | 0 | 0 |
| 1663 | 3 | 32 | 205 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
| 1664 | 14 | 24 | 1970 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
| 1665 | 5 | 12 | 1677 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 5 | 7 |
| 1666 | 22 | 33 | 549 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
| 1667 | 0 | 0 | 505 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
| 1668 | 16 | 23 | 583 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
| 1669 | 0 | 0 | 1025 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| 1670 | 5 | 5 | 479 1995 MOLECULAR MEDICINE TODAY 1(5):210-210 STEWART A IS THALIDOMIDE A MUTAGEN | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 15 | 17 | 1275 2001 SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 8 | 13 |
| 1672 | 66 | 87 | 742 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
| 1673 | 51 | 96 | 1049 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
| 1674 | 0 | 0 | 1508 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
| 1675 | 0 | 37 | 1900 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
| 1676 | 30 | 59 | 1390 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
| 1677 | 0 | 0 | 1674 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| 1678 | 24 | 28 | 1234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
| 1679 | 3 | 4 | 321 1992 GENITOURINARY MEDICINE 68(6):424-425 STRAZZI S; LEBBE C; GEOFFRAY C; ABLON G; MOREL P; VEROLA O; MOLINA JM APHTHOUS ULCERS IN HIV-INFECTED PATIENTS - TREATMENT WITH THALIDOMIDE | 8 | 10 |
| 1680 | 0 | 1 | 24 1981 POLITICAL QUARTERLY 52(1):135-136 STREET H THE SUNDAY-TIMES THALIDOMIDE CASE - CONTEMPT OF COURT AND THE FREEDOM OF THE PRESS - ROSEN,M | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 0 | 31 | 322 1992 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 230(2):140-149 STROMLAND K; MILLER MT REFRACTIVE EVALUATION IN THALIDOMIDE EMBRYOPATHY | 3 | 5 |
| 1682 | 1 | 33 | 346 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
| 1683 | 2 | 19 | 403 1994 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 36(4):351-356 STROMLAND K; NORDIN V; MILLER M; AKERSTROM B; GILLBERG C AUTISM IN THALIDOMIDE EMBRYOPATHY - A POPULATION STUDY | 3 | 71 |
| 1684 | 17 | 35 | 1553 2002 TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 3 | 5 |
| 1685 | 5 | 24 | 1519 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 1686 | 7 | 22 | 1517 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 15 | 26 |
| 1687 | 16 | 28 | 1896 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
| 1688 | 5 | 8 | 1781 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| 1689 | 9 | 31 | 1695 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 3 | 3 |
| 1690 | 0 | 0 | 655 1998 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 2 | 9 | 731 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 21 |
| 1692 | 2 | 12 | 847 1999 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
| 1693 | 9 | 20 | 1774 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
| 1694 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
| 1695 | 7 | 26 | 299 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 27 |
| 1696 | 0 | 0 | 133 1984 TERATOLOGY 30(1):A36-A36 TANAKA Y THALIDOMIDE-INDUCED OTOLARYNGOLOGICAL DEFECTS | 0 | 0 |
| 1697 | 0 | 3 | 1959 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |
| 1698 | 5 | 32 | 648 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 24 | 39 |
| 1699 | 0 | 0 | 844 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 1700 | 1 | 3 | 942 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 24 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 3 | 5 | 415 1994 LANCET 344(8916):196-197 TEIXEIRA F; HOJYO MT; ARENAS R; VEGA ME; CORTES R; ORTIZ A; DOMINGUEZ L THALIDOMIDE - CAN IT CONTINUE TO BE USED | 4 | 4 |
| 1702 | 6 | 10 | 1795 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
| 1703 | 3 | 5 | 397 1994 BRITISH MEDICAL JOURNAL 309(6966):1442-1442 TENCONI R; CLEMENTI M; NOTARI L; VASCO VRLO AMNIOTIC BAND SEQUENCE IN CHILD OF THALIDOMIDE VICTIM | 4 | 6 |
| 1704 | 19 | 40 | 987 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
| 1705 | 13 | 22 | 1056 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
| 1706 | 7 | 11 | 1281 2002 AIDS 16(17):2355-2356 Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing | 1 | 1 |
| 1707 | 16 | 24 | 1480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
| 1708 | 8 | 15 | 826 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| 1709 | 42 | 65 | 1890 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 1 | 1 |
| 1710 | 29 | 56 | 1973 2004 TOXICOLOGICAL SCIENCES 81(2):379-389 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth S; Hoberman AM Effects of thalidomide on developmental, peri-and postnatal function in female New Zealand white rabbits and offspring | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 24 | 47 | 1857 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 1 | 1 |
| 1712 | 23 | 52 | 1278 2001 TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 5 | 5 |
| 1713 | 8 | 13 | 1182 2001 DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 8 | 13 |
| 1714 | 4 | 38 | 1532 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
| 1715 | 15 | 25 | 999 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
| 1716 | 13 | 33 | 895 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
| 1717 | 20 | 32 | 1224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
| 1718 | 9 | 29 | 818 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
| 1719 | 2 | 7 | 559 1996 REVISTA CLINICA ESPANOLA 196(4):270-271 Tercedor J; delaTorre ML; Rodenas JM Disseminated xanthoma with insipid diabetes: Therapeutic failure of thalidomide | 0 | 0 |
| 1720 | 0 | 0 | 313 1991 MEDICINA CLINICA 97(2):79-79 TERCEDOR J; ORTEGO N; RODENAS JM; HERNANDEZ J TREATMENT OF RECURRENT APHTHAE WITH THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 0 | 0 | 172 1985 TERATOLOGY 31(3):A68-A68 TESH JM; NEWALL DR TERATOGENIC EFFECTS OF THALIDOMIDE ON RAT EMBRYOS INVITRO | 0 | 1 |
| 1722 | 0 | 0 | 195 1986 TERATOLOGY 33(2):A48-A49 TESH JM; NEWALL DR THALIDOMIDE AND ABNORMAL EMBRYONIC-DEVELOPMENT INVITRO | 0 | 0 |
| 1723 | 6 | 26 | 663 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
| 1724 | 0 | 0 | 996 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| 1725 | 0 | 0 | 99 1983 TERATOLOGY 27(2):A80-A80 THEISEN CT THALIDOMIDE DYSMELIA IN RHESUS-MONKEYS - AN OVERVIEW | 0 | 0 |
| 1726 | 0 | 0 | 32 1981 TERATOLOGY 23(2):A65-A65 THEISEN CT; MCGREGOR EE FURTHER OBSERVATIONS ON THE DEVELOPMENT OF THALIDOMIDE INDUCED LIMB DEFORMITIES | 4 | 7 |
| 1727 | 5 | 16 | 1020 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 1728 | 0 | 0 | 733 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| 1729 | 19 | 36 | 1445 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
| 1730 | 3 | 13 | 1021 2000 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 7 | 35 | 1052 2000 SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
| 1732 | 0 | 0 | 779 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 1733 | 0 | 0 | 784 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 1734 | 9 | 20 | 1684 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 1 | 2 |
| 1735 | 45 | 95 | 965 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
| 1736 | 21 | 30 | 1073 2001 ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
| 1737 | 17 | 41 | 348 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
| 1738 | 13 | 25 | 1589 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
| 1739 | 0 | 0 | 473 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
| 1740 | 10 | 33 | 1579 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 4 | 10 | 1683 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 1742 | 0 | 0 | 1385 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| 1743 | 9 | 9 | 1226 2001 JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147 Thomson KF; Goodfield MJD Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus | 0 | 2 |
| 1744 | 0 | 68 | 1054 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 1745 | 5 | 11 | 1673 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 1746 | 9 | 9 | 825 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
| 1747 | 0 | 2 | 40 1982 ARCHIVES OF DERMATOLOGY 118(11):875-875 TORRAS H; LECHA M; MASCARO JM THALIDOMIDE TREATMENT OF RECURRENT NECROTIC GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 18 | 24 |
| 1748 | 18 | 23 | 1459 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| 1749 | 17 | 33 | 1202 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
| 1750 | 0 | 0 | 922 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 0 | 0 | 1629 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
| 1752 | 11 | 26 | 1898 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| 1753 | 0 | 0 | 1105 2001 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 1754 | 15 | 35 | 1463 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |
| 1755 | 4 | 18 | 478 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 131 |
| 1756 | 8 | 27 | 693 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 1757 | 4 | 40 | 1505 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
| 1758 | 0 | 0 | 1198 2001 GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
| 1759 | 0 | 0 | 1388 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| 1760 | 1 | 6 | 125 1984 REVUE DU RHUMATISME 51(10):585-585 TREVES R; ARNAUD M; JACOB P; LUBEAU M; TABARAUD F; BURKI F; DESPROGESGOTTERON R DRAMATIC IMPROVEMENT IN THE ARTHRITIS OF BEHCETS-DISEASE FOLLOWING THE ADMINISTRATION OF THALIDOMIDE - A CASE-REPORT | 3 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 3 | 4 | 1276 2001 SWISS MEDICAL WEEKLY 131(9-10):133-133 Trojan A; Anagnostara A; Fost L Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma | 2 | 2 |
| 1762 | 9 | 9 | 1578 2003 ANNALS OF ONCOLOGY 14(3):501-502 Trojan A; Chasse E; Gay B; Pichert G; Taverna C Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | 2 | 2 |
| 1763 | 0 | 0 | 1862 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
| 1764 | 8 | 25 | 381 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
| 1765 | 31 | 67 | 1160 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 7 | 14 |
| 1766 | 74 | 101 | 546 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 78 | 117 |
| 1767 | 9 | 36 | 1299 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
| 1768 | 0 | 1 | 1300 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002) | 0 | 0 |
| 1769 | 9 | 41 | 710 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
| 1770 | 5 | 9 | 1559 2003 ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 3 | 5 | 1525 2002 LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
| 1772 | 0 | 0 | 57 1982 TERATOLOGY 26(1):A4-A4 TSUCHIYA K THALIDOMIDE EMBRYOPATHY AND ITS ALLIED CONDITIONS IN JAPAN | 0 | 0 |
| 1773 | 0 | 0 | 537 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):572-572 Tsujikawa M; Saito Y; Tatebayashi M; Tano Y The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. | 0 | 0 |
| 1774 | 0 | 0 | 1662 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
| 1775 | 30 | 49 | 1178 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
| 1776 | 10 | 32 | 557 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 40 | 50 |
| 1777 | 6 | 40 | 1732 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 2 |
| 1778 | 0 | 0 | 1111 2001 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 1779 | 5 | 5 | 1318 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 13 | 18 |
| 1780 | 10 | 24 | 433 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 0 | 0 | 1132 2001 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
| 1782 | 1 | 18 | 76 1983 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE 96(7):910-913 VAISMAN BL; POPOV VP; IGNATEVA TV REDUCTION IN THE TISSUE ASCORBIC-ACID LEVEL IN GUINEA-PIGS BY THALIDOMIDE | 1 | 2 |
| 1783 | 1 | 5 | 1593 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
| 1784 | 18 | 27 | 1301 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
| 1785 | 6 | 16 | 953 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 1786 | 7 | 20 | 973 2000 EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
| 1787 | 11 | 21 | 1246 2001 NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
| 1788 | 0 | 0 | 575 1997 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
| 1789 | 0 | 16 | 47 1982 EUROPEAN JOURNAL OF PEDIATRICS 138(1):77-80 VANREGEMORTER N; HAUMONT D; KIRKPATRICK C; VISEUR P; JEANTY P; DODION J; MILAIRE J; ROOZE M; RODESCH F HOLT ORAM SYNDROME MISTAKEN FOR THALIDOMIDE EMBRYOPATHY - EMBRYOLOGICAL CONSIDERATIONS | 1 | 6 |
| 1790 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 0 | 805 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 1792 | 0 | 0 | 1596 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
| 1793 | 0 | 0 | 993 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 1794 | 0 | 0 | 819 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| 1795 | 0 | 0 | 37 1982 ANNALES DE PEDIATRIE 29(1):67-69 VENENCIE PY; SAURAT JH PYODERMA GANGRENOSUM IN A CHILD - TREATMENT WITH THALIDOMIDE | 20 | 36 |
| 1796 | 0 | 20 | 71 1983 BRITISH MEDICAL JOURNAL 286(6360):199-202 VENNING GR IDENTIFICATION OF ADVERSE REACTIONS TO NEW DRUGS .1. WHAT HAVE BEEN THE IMPORTANT ADVERSE REACTIONS SINCE THALIDOMIDE | 0 | 59 |
| 1797 | 0 | 0 | 907 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| 1798 | 0 | 0 | 1430 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
| 1799 | 2 | 5 | 547 1996 LANCET 347(9006):974-974 Verberkmoes A; Boer K; Wertheim PME; Bronkhorst CM; Lange JMA Thalidomide for genital ulcer in HIV-positive woman | 4 | 9 |
| 1800 | 17 | 32 | 887 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |